SINGAPORE, BOSTON and SHANGHAI, June 28, 2022 /PRNewswire/ Cargene Biopharma Inc. ("Cargene", the "Company"), a biopharmaceutical company developing oligonucleotide therapeutics for liver and ophthalmic disorders, is excited to welcome Kathy He, a seasoned biopharmaceutical industry executive, to join the Company as Chief Executive Officer and a member of the board. Kathy brings over 20 years of R&D and commercial experience from multiple global companies to her new role at Cargene, notably in building differentiated product portfolios, developing strategic opportunities, and successfully bringing innovative therapeutics to market. Based in Singapore, Boston and Shanghai, Cargene Biopharma aims to leverage its novel biology and chemistry insights to develop highly specific, stable and potent nucleic acid therapeutics for a broad range of diseases. In December 2021, the Company successfully closed a pre-Series A funding round of nearly US$20 million, led by Bio